Suchergebnisse - "Zhou, Jianying"

PubPharm (141)

1

HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Jiang, T. | Jin, Q. | Wang, J. | +38

CommentIn: Clin Cancer Res. 2023 Dec 1;29(23):4706-4708. - PMID 37756560

2

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer : a multicentre, open-label, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2023

von Lu, S. | Zhou, J. | Jian, H. | +41

CommentIn: Lancet Respir Med. 2023 Oct;11(10):857-859. - PMID 37244264

3

Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study : a case report

enthalten in: Anti-cancer drugs | 2023

von Wu, L. | Cheng, Y. | Huang, D. | +7

4

Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Zheng, J. | Li, Y. | Jin, C. | +7

5

Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia

enthalten in: Immunotherapy | 2023

von Cheng, Y. | Yang, J. | Okamoto, I. | +17

6

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer : a randomized, multicenter, open-label, phase III trial

enthalten in: Signal transduction and targeted therapy | 2023

von Yang, Y. | Min, J. | Yang, N. | +17

7

Immunomodulatory effects of CDK4/6 inhibitors

enthalten in: Biochimica et biophysica acta. Reviews on cancer | 2023

von Zhang, S. | Xu, Q. | Sun, W. | +2

8

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

9

Interim survival analysis of the randomized phase III GEMSTONE-302 trial : sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

enthalten in: Nature cancer | 2023

von Zhou, C. | Wang, Z. | Sun, M. | +31

ErratumIn: Nat Cancer. 2024 Jan 5;:. - PMID 38182915

10

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

enthalten in: JCO precision oncology | 2023

von Cheng, Y. | Huang, D. | Zhou, J. | +7

ErratumIn: JCO Precis Oncol. 2023 Sep;7:e2300420. - PMID 37656952

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[15]